Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Depreciation & Amortization (CF): 2012-2025

Historic Depreciation & Amortization (CF) for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $1.3 million.

  • Enanta Pharmaceuticals' Depreciation & Amortization (CF) rose 168.06% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 96.32%. This contributed to the annual value of $4.6 million for FY2025, which is 96.32% up from last year.
  • Enanta Pharmaceuticals' Depreciation & Amortization (CF) amounted to $1.3 million in Q3 2025, which was up 6.12% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $1.3 million during Q3 2025, and its lowest value of $479,000 during Q3 2024.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $651,000 (2023), whereas its average is $798,364.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first crashed by 34.49% in 2022, then skyrocketed by 168.06% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $780,000 in 2021, then tumbled by 34.49% to $511,000 in 2022, then grew by 25.64% to $642,000 in 2023, then spiked by 38.47% to $889,000 in 2024, then surged by 168.06% to $1.3 million in 2025.
  • Its Depreciation & Amortization (CF) was $1.3 million in Q3 2025, compared to $1.2 million in Q2 2025 and $1.2 million in Q1 2025.